How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?

Weight loss drug Wegovy made Novo Nordisk Europe’s most valuable company, according to Fortune, but the firm is now finding its next blockbuster drug difficult to secure. Reuters adds that the obesity battle has heated again as Novo claws its way back into the race with Eli Lilly. The collection of headlines therefore signals a transition from clear market dominance to a contested race for new cardiometabolic products. Fortune’s coverage emphasizes the valuation surge and the pipeline challenge, while Reuters spotlights the renewed rivalry with Lilly.

Endpoints News describes the second‑quarter period as a cardiometabolic “grudge match” between the two manufacturers. BioPharma Dive reports that Lilly is climbing as Novo falls, noting that the obesity drug battle is intensifying. The Economist observes that Novo is taking another shot at Lilly, and MarketWatch questions how Novo blew its GLP‑1 lead and whether Europe can compete in the high‑stakes global economy. Europe’s biotech sector, represented by Novo, now faces pressure to sustain innovation amid intensifying global competition.

Upcoming developments will likely focus on any pipeline disclosures from Novo Nordisk, potential regulatory filings, and Lilly’s next product roll‑outs, as both companies vie for dominance in the cardiometabolic space. Analysts will also monitor European policy responses and investment trends that could affect the region’s capacity to compete in the global GLP‑1 market. The trajectory of market share and the timing of new drug launches will be key indicators of who regains the lead.